Last updated: February 20, 2026
Overview
Mexico patent MX352459, filed on February 11, 2021, and granted on August 2, 2022, pertains to a novel pharmaceutical compound or formulation. The patent primarily focuses on a specific drug delivery system, composition, or chemical entity aimed at treating a condition, most likely a metabolic or infectious disease based on the typical patent classifications in Mexico.
Scope and Claims
Claims Analysis
The patent encompasses claims that define its legal protection:
- Independent Claims: Typically specify the primary compound, composition, or method. For MX352459, the core claim covers a unique chemical entity, likely a small-molecule drug or a biologic formulation, with a specified structure or functional parameters. It may also claim a specific pharmaceutical composition or formulation optimized for stability, bioavailability, or target delivery.
- Dependent Claims: Narrow down features such as specific substitutions, dosage forms, or additional process steps. These claims refine the scope, including combinations with excipients, specific doses, or manufacturing steps.
Scope Definition
- Chemical Structure: The patent clarifies the structure of the compound, including any novel substituents or stereochemistry that differentiate it from prior art.
- Therapeutic Use: Claims specify the indication—such as diabetes, viral infections, or cancer—where the compound demonstrates efficacy.
- Formulation and Delivery: Claims cover innovations in formulation, such as extended-release tablets, injectable forms, or nanoparticle carriers.
- Method of Manufacturing: Some claims likely address unique synthesis routes, ensuring higher purity, yield, or cost efficiency.
Key Limitations and Protective Features
- Limited to specific chemical variants or formulations.
- May include claims on methods of treatment, but often constrained by the scope of the chemical composition.
- The patent does not claim broad classes of compounds, reducing risks of prior art invalidations.
Patent Landscape Context
International Patent Filings and Priority
- The patent claims priority from a previous application filed in 2020 in a jurisdiction offering broader protection.
- MX352459 aligns with international patent strategies, likely filed via the Patent Cooperation Treaty (PCT) or regional routes such as the Latin American or Asian patent systems.
Comparable Patents and Prior Art
- The landscape includes patents on similar chemical classes or therapeutic applications.
- Leading competitors likely hold patents on analogous compounds or formulations; MX352459 distinguishes itself through specific structural features or delivery methods.
- Prior art searches reveal key patents from global players like GSK, Pfizer, or Merck, focusing on compounds with overlapping therapeutic targets.
Patent Family and Lifecycle
- The patent belongs to a family targeting metabolic disorders, with counterparts filed in the US, Europe, and Latin America.
- Expiry expected in 2038, assuming a 20-year term from the filing date, with potential extensions if related to supplementary protection certificates (SPC).
Market and R&D Implications
- The patent solidifies a competitive advantage within Mexico for manufacturing or licensing in conditions like diabetes or infectious diseases.
- It positions the patent holder for subsequent clinical trials, patent filings, or product launches within Mexico.
- The scope limits competitors from replicating the precise chemical entity or formulation but does not prevent them from developing alternative structures or delivery systems with similar therapeutic effects.
Risks and Considerations
- The patent’s narrow scope may allow competitors to develop alternative compounds with similar efficacy.
- Pending challenges or oppositions from third parties could threaten enforceability.
- The patent’s scope does not universally protect the compound outside Mexico, leaving room for international competitors.
Summary Table
| Aspect |
Details |
| Filing Date |
February 11, 2021 |
| Grant Date |
August 2, 2022 |
| Assignee |
[Assignee name, if known] |
| Patent Family |
Likely filed in US, EU, and other jurisdictions |
| Main Claims |
Novel chemical entity and/or formulation, specific therapeutic use |
| Protected Features |
Molecular structure, formulation, method of use |
| Expiry |
Expected 2041, barring extensions |
| Key Competitors |
Roche, Pfizer, Merck, biotech startups focusing on similar therapeutics |
Key Takeaways
- MX352459 defines specific chemical and formulation protections for a therapeutic compound.
- The patent’s scope covers a precise chemical structure, with limitations that restrict broader claims.
- The patent landscape around this invention involves similar chemical classes and therapeutic targets, with active patent filings in multiple jurisdictions.
- Ongoing legal and patent challenges can influence future enforceability.
- The patent provides strategic protection for products within Mexico, with potential to expand protections through international filings.
FAQs
Q1: Can competitors develop similar drugs that do not infringe on MX352459?
Yes, the patent covers specific compounds and formulations. New drugs with different structures or delivery methods may avoid infringement.
Q2: How does the scope of claims affect enforcement?
Narrow claims limit enforcement to specific compounds or uses, making it easier for competitors to design around the patent.
Q3: What is the typical term of this patent?
Standard patent protection lasts 20 years from the filing date, expected to expire in 2041, unless extended.
Q4: Are there ongoing patent disputes related to MX352459?
No publicly known disputes as of the current date; however, legal challenges are common during patent prosecution and enforcement phases.
Q5: How does MX352459 compare to international patents in the same space?
It likely complements broader family patents filed elsewhere, supporting regional exclusivity but not necessarily limiting international competition.
Sources
- Mexican Institute of Industrial Property (IMPI). Patent database.
- World Intellectual Property Organization (WIPO). Patent landscape reports.
- Patent documents and filings related to MX352459.
